RAMESH KUMAR, Ph.D.
PRESIDENT AND CEO
Dr. Kumar is a co-founder of Onconova. He received his Ph.D. in Molecular Biology from the University of Illinois, Chicago, and trained at the National Cancer Institute. He has held positions in R&D or management at Princeton University, Bristol-Myers Squibb, DNX (later Nextran, a subsidiary of Baxter) and Kimeragen (later Valigen), where he was President of the Genomics and Transgenics Division. Dr. Kumar has more than 50 publications spanning the areas of molecular oncology, transgenic animals, gene therapy and recombination. He is an inventor in 8 U.S. patents and many patent applications. He co-edited the 1993 book "Molecular Basis of Human Cancer".
rkumar@onconova.us
JAMES R. ALTLAND
SENIOR VP FINANCE &
CORPORATE DEVELOPMENT
Mr. Altland is a CPA in Ohio and is a graduate of the University of Akron. He was a Partner of Tatum LLC where, as the Senior Partner in the Philadelphia office, he was Practice Leader for the life science segment. Mr. Altland served as CFO at LifeTime Pharmaceuticals and NorthStar Research & Development, Ltd. He is the former President and CEO of JRA Consulting, where he provided consulting services to early stage life science and technology companies. During his earlier years he held various management positions with Dietrich's Milk Products, IFR Furniture Rentals, IC Industries/Whitman's Chocolates, Tasty Baking Co. and The JM Smucker Company.
jaltland@onconova.us
MANOJ MANIAR, Ph.D.
SENIOR VICE PRESIDENT,
PRODUCT DEVELOPMENT
Dr. Maniar received his B.S. in Pharmacy from Bombay College and his Ph.D. in Pharmaceutics from the University of Connecticut. He has led the development and commercialization of several pharmaceutical products and medical devices during his career. Prior to joining Onconova, Dr. Maniar was with SRI International, where he served as Senior Director, Formulations and Drug Delivery. He has authored more than 100 patents, publications, and presentations in the field of pharmaceutical sciences.
mmaniar@onconova.us
FRANCOIS E. WILHELM, M.D., Ph.D.
CHIEF MEDICAL OFFICER AND
SENIOR VICE PRESIDENT
Dr. Wilhelm is Board Certified in Rheumatology, receiving his medical degree from Paris University Medical School, his Ph.D. in Endocrinology and a Master's degree in Biostatistic, both from the University of Paris. He has 23 years of clinical development experience covering all phases of drug development and post-marketing in Europe (Hoffmann-La Roche) and in the U.S. (Fujisawa, Pfizer, Procter & Gamble, Akros Pharma, Johnson and Johnson). He has been involved in clinical development programs in oncology-hematology, immunology, inflammation, virology, bone metabolism, endocrinology, women's health, coagulation and lipid metabolism. He has authored more than 30 publications.
fwilhelm@onconova.us
SCOTT T. MEGAFFIN
SENIOR VICE-PRESIDENT,
COMMERCIAL
Mr. Megaffin has extensive experience in all commercial aspects of pharmaceutical and biotechnology products, with exposure to large, mid-size and small companies. He earned a Bachelor of Science degree in Biology from Pittsburg State University. Scott is responsible for business development and commercial strategy for the Onconova pipeline of products. He joined Onconova in December of 2009 bringing after over 20 years of relevant experience including leadership assignments. Prior to joining Onconova, Scott led commercial development activities in key therapeutic areas for Cephalon, Adolor, Yamanouchi, Pharmacia / Pfizer, and Bristol-Myers Squibb. He has held positions of increasing responsibility which have included global launches and strategic planning within Virology, Critical Care, Anti-Infectives, as well as, Pain and Inflammation.
smegaffin@onconova.us
DAVE STEPHON
SENIOR VICE-PRESIDENT,
QUALITY MANAGEMENT
Mr. Stephon has more than twenty five (25) years experience in the pharmaceutical industry with in depth experience in regulatory compliance and quality management systems. His experience includes senior management positions in quality assurance at several pharmaceutical companies where he has been responsible for design and implementation of GxP training programs, design and implementation of GxP vendor/CRO assessment programs, six sigma and modern quality management system design, review and assessment of global regulatory filings and coordination of preparation activities for GCP and GMP pre-approval FDA field inspections. His most recent position in industry was Vice President, Quality Management at Adolor Corporation where he was responsible for GCP, GLP and GMP quality management operations and the successful management of all FDA inspections for the company's first NDA approval.
dstephon@onconova.us
ROBERT MAGUIRE
DISTINGUISHED CLINICAL FELLOW
Mr. Maguire was educated at Princeton University and Temple University Medical School. He did his residency at Duke University Medical School and a Pediatric Oncology fellowship at the National Institutes of Health. He has been in the pharmaceutical industry for 27 years, including 12 years heading up CR&D at Cytogen, a monoclonal antibody/oncology biotechnology company where he was responsible for 3 FDA approvals. Bob also served as Chief Scientific Officer for Targon Corp, a joint venture between Cytogen and Elan. In addition, Bob spent 15 years with Wyeth Pharmaceuticals where he has held positions responsible for designing and executing clinical trials across multiple therapeutic areas, including Oncology, Hematology, Inflammation, and Cardiovascular/Metabolic. More recently he has been responsible for the Clinical Development group tasked with execution of the company's global clinical trials programs. In 2009 this group enrolled approximately 100,000 patients in over 250 clinical studies conducted at 9,000 investigative sites. Bob received the President's Achieving Excellence Award for his work on the team that designed and implemented the Learn and Confirm paradigm at Wyeth.
rmaguire@onconova.us
STANLEY C. BELL, Ph.D
1931-2009
Visit the Stanley C. Bell memorial page
